Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV in Brazilian transgender women (PrEParadas)

Phase:Demo Project
Principal Investigator(s):
Objective:A prospective, open, study of PrEP, which aims to assess the acceptability, feasibility and safety from chemoprophylaxis co-formulated emtricitabine / tenofovir disoproxil fumarate (FTC / TDF) administered orally, once daily, to transgender women . The demonstration project aims to include 120 participants over 48 months, at INI-Fiocruz.
Prevention Option(s):PrEP
Study Design:
Trial Sponsors: Brazilian Ministry of Health
Start Date
End Date
July 12, 2018
July 2, 2020
Age range: ↔ any